This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by McGuire, M. Articles by Dobesh, P. P. Search for Related Content Social Bookmarking                         What's this?

Therapeutic Update on the Prevention and Treatment of Venous Thromboembolism

Kos Pharmaceuticals, 125 West Third Avenue, Conshohocken, Pennsylvania 19428

Paul P. Dobesh, PharmD, BCPS

Division of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, Missouri, St. Luke's Hospital, Chesterfield, Missouri

Venous thromboembolism (VTE) is a common condition that increases in incidence with age and risk factors. Therapies for VTE are aimed at either preventing the disease in high-risk individuals or treating patients who have developed VTE. Assessing risk and aggressively using the recommended therapies is primacy in preventing VTE in surgical and medical patients. Risk of VTE in medical patients has become more defined in recent years, and prophylaxis in this group can prevent scores of iatrogenic VTE. Treatment of VTE has evolved in the past decade from a condition that required hospitalization for 5 to 7 days to a disease state that can be conveniently and safely treated on an outpatient basis, largely due to the advent of low-molecular-weight heparins and patient self-directed treatment.

Key Words: Venous thromboembolism • self-directed treatment • low-molecular-weight heparins

Journal of Pharmacy Practice, Vol. 17, No. 5, 289-307 (2004)
DOI: 10.1177/0897190004271779


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?